| abstract |
A method of treating a subject having reduced arginine or nitric oxide bioavailability as a symptom or cause of a disorder. The method comprises administering L-arginine and an arginase inhibitor such as N (ω) -hydroxy-nor-L-arginine (NOHA) and / or magnesium to a subject in need of treatment. Is effective in enhancing the bioavailability of arginine or nitric oxide in a subject, thereby treating asthma, sickle cell disease, pulmonary hypertension, etc. in the subject. [Selection] Figure 1 |